Anterior optic neuropathy associated with adalimumab.
OBJECTIVE
Our purpose was to report a case of anterior optic neuropathy with pupillary edema in a patient treated with the TNF-alpha-antagonist adalimumab.


METHODS
We report the case of a 60-year-old woman with optic neuropathy in 1 eye after 6 months of treatment with adalimumab.


RESULTS
The patient developed decreased visual acuity of the left eye. The ocular findings were left optic disc swelling and bleeding at the rim, superior visual field depression in both eyes and left afferent pupillary defect. Adalimumab was discontinued and the visual acuity recovered slowly.


CONCLUSIONS
Like infliximab, the modern TNF-alpha antagonist adalimumab is associated with optic neuropathy. Ophthalmologists should thus be alert when seeing patients treated with adalimumab.
Department of Ophthalmology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
Burkhard
B
von Jagow
Thomas
T
Kohnen
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008875:Middle Aged; D009901:Optic Nerve Diseases / Q000139:chemically induced* / Q000175:diagnosis; D010211:Papilledema / Q000139:chemically induced / Q000175:diagnosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D058609:Visual Field Tests; D014794:Visual Fields
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab